Hims & Hers Health Inc

Hims & Hers Health, Inc. (NYSE: HIMS) provides a consumer-first platform, which helps customers to fulfill their health and wellness needs. Its platform includes access to a provider network, a clinically focused electronic medical record system, digital prescriptions, cloud pharmacy fulfillment, and personalization capabilities. Its digital platform enables access to treatments for a range of chronic conditions, including those related to sexual health, hair loss, dermatology, mental health, and weight loss.

Key Business and Financial Updates:

• Strong Revenue & Subscriber Growth: Hims & Hers delivered revenue of nearly USD 599 million in Q3 2025, representing 49% year-over-year growth. Subscriber count rose to approximately 2.47 million, up 21% from a year earlier, while monthly online revenue per average subscriber increased to USD 80, a 19% increase from the prior year quarter. These metrics underscore the company’s ability to scale its platform and expand customer engagement across its health and wellness offerings.
• Profitability and Margins: In Q3, the company achieved net income of about USD 15.8 million and Adjusted EBITDA of USD 78.4 million, up from USD 51.1 million a year ago — a growth of approximately 53%. Gross margin was 74%, down from 79% in the same quarter last year, reflecting margin compression likely from evolving mix and investment. Operating cash flow reached USD 148.7 million, while free cash flow was reported at USD 79.4 million — matching the prior year, indicating the business is generating healthy cash despite margin pressures.
• Strategic Business & Platform Expansion: CEO Andrew Dudum emphasized that the company’s vision of providing personalized, high-quality care at scale is gaining traction, with new specialties being launched and the platform advancing into more proactive health-care services. CFO Yemi Okupe noted that the model continues to scale profitably, and that Hims & Hers is in a strong position to invest in long-term growth, citing international expansion and deeper service offerings as key drivers for the future.
• Outlook and Guidance: For the full year 2025, the company narrowed its guidance to revenue of USD 2.335 billion to USD 2.355 billion and Adjusted EBITDA of USD 307 million to USD 317 million, implying an EBITDA margin near 13%. For Q4, Hims & Hers expects revenue of USD 605 million to USD 625 million and Adjusted EBITDA of USD 55 million to USD 65 million (roughly 9-10% margin). The guidance reflects confidence but also acknowledges near-term margin pressure as investment in growth continues.
• Growth Levers and Risks: Key growth levers described by management include expanding the breadth of care specialties, improving personalization, global expansion, and deepening digital engagement with consumers. Hims & Hers is also in active discussions with Novo Nordisk to make Wegovy injections and future oral versions available via its platform, highlighting a potential new revenue stream albeit with regulatory and deal-execution risk. While the company is profitable, margin declines and dependency on emerging service lines pose risks, as do competitive and regulatory dynamics in tele-health and compounded drug markets.

Technical Observation (on the daily chart):

• Price Trend and Moving Averages: Hims & Hers Health Inc. (HIMS) trades at USD 44.39, below its 50-day (USD 51.41) and 200-day (USD 46.48) averages, indicating short-term weakness. The sustained move under key averages reflects bearish momentum and continued selling pressure.
• Support and Resistance Analysis: The stock faces support near USD 44.00–43.50, with further downside risk toward USD 40.00 if breached. Resistance is seen at around USD 51.00 and USD 55.00, levels that need to be cleared for a recovery signal.
• Momentum and Market Sentiment: The RSI at 38.44 suggests weak momentum and mild oversold conditions. While a short-term rebound is possible, overall sentiment remains cautious until the stock reclaims levels above its key moving averages.

Individuals can evaluate the stock based on the support and resistance levels provided in the report in case of keen interest taking into consideration the risk-reward scenario. 

Markets are trading in a highly volatile zone currently due to certain macro-economic issues and prevailing geopolitical tensions. Therefore, it is prudent to follow a cautious approach while investing.

Related Risk: This report may be looked at from a high-risk perspective, and a recommendation is provided for a short duration. This report is solely based on technical parameters, and the fundamental performance of the stocks has not been considered in the decision-making process. Other factors which could impact the stock prices include market risks, regulatory risks, interest rates risks, currency risks, social and political instability risks etc. 

Note 1: Past performance is not a reliable indicator of future performance.

Note 2: The reference date for all price data, currency, technical indicators, support, and resistance level is November 03, 2025. The reference data in this report has been partly sourced from REFINITIV.

Note 3: Investment decisions should be made depending on an individual's appetite for upside potential, risks, holding duration, and any previous holdings. An 'Exit' from the stock can be considered if the Target Price mentioned as per the Valuation and or the technical levels provided has been achieved and is subject to the factors discussed above.

Note 4: Target Price refers to a price level that the stock is expected to reach as per the relative valuation method and or technical analysis taking into consideration both short-term and long-term scenarios.

Note 5: ‘Kalkine reports are prepared based on the stock prices captured either from the New York Stock Exchange (NYSE), NASDAQ Capital Markets (NASDAQ), and or REFINITIV. Typically, all sources (NYSE, NASDAQ, or REFINITIV) may reflect stock prices with a delay which could be a lag of 15-20 minutes. There can be no assurance that future results or events will be consistent with the information provided in the report. The information is subject to change without any prior notice.